U.S. announces deal with Pfizer in vaccine effort

Contract worth nearly $2B; it calls for 100 million doses

WASHINGTON — As nations around the world race to lock up coronavirus vaccines, the Trump administration on Wednesday announced a nearly $2 billion contract with Pfizer and a German biotechnology company for 100 million doses by December.

The contract is part of what the White House calls the Warp Speed project, an effort to drastically shorten the time it would take to manufacture and distribute a working vaccine. So far, the United States has put money into more than a half-dozen efforts, hoping to build manufacturing ability for an eventual breakthrough.

Europe has a parallel effort underway. Germany recently took a 23% stake in a German firm, CureVac, that President Donald Trump once tried to lure to American shores in the hopes that its vaccine, if successful, would be distributed in the United States first. A European-led fundraising effort in May brought $8 billion in pledges from the world’s governments, philanthropists and leaders for coronavirus vaccine research, even with the United States sitting out the conference.

China has militarized the effort: Researchers associated with the Academy of Military Medical Sciences have developed one of China’s leading vaccine candidates, and another Chinese company, Sinopharm Group, announced in June that it was beginning Phase 3 trials in the United Arab Emirates.

The Pfizer contract, an agreement to ensure the pharmaceutical giant has a market for its work, is the biggest splash yet by the Americans. If the vaccine being produced by Pfizer and BioNTech, the German firm, proves to be safe and effective in clinical trials, the companies say they could manufacture those first 100 million doses by the end of the year.

Under the arrangement, the federal government would obtain that first batch for $1.95 billion, or about $20 a dose, with the rights to acquire up to 500 million more, or 600 million total. Americans would receive the vaccine for free. Before it could be distributed, it would need emergency approval by the Food and Drug Administration. But the U.S. government does not pay the nearly $2 billion until the drug is approved and the first 100 million doses are delivered.

GETTING TO TRIALS

Pfizer said that large-scale safety and efficacy trials were to begin this month, with regulatory review set for as early as October, although nothing was guaranteed.

“Depending on success in clinical trials, today’s agreement will enable the delivery of approximately 100 million doses of vaccine being developed by Pfizer and BioNTech,” Health and Human Services Secretary Alex Azar said in a statement announcing the deal.

On Monday, Pfizer and AstraZeneca, a British-Swedish drug company developing a potential vaccine with Oxford University, released data suggesting that their vaccines could stimulate strong immune responses with only minor side effects.

But unlike AstraZeneca, which has also obtained funding from the U.S. government, Pfizer did not receive a contract for its earlier research and development efforts — only for the doses and their distribution.

By refusing funding until now, Pfizer was able to avoid drawn-out contractual negotiations and get its vaccine to trials, company officials say.

“We didn’t accept the federal government funding solely for the reason that we wanted to be able to move as quickly as possible with our vaccine candidate into the clinic,” John Young, Pfizer’s chief business officer, said Tuesday at a congressional hearing with executives from five vaccine manufacturers.

Pfizer and BioNTech are developing a vaccine candidate that uses genetic material from the virus, known as messenger RNA, to stimulate the immune system without making the recipient sick. The technology can create a vaccine quickly, but it has not yet produced one that has been approved and marketed.

Moderna, a Massachusetts-based biotech company, received $483 million from the U.S. government for its vaccine development and is also using mRNA technology. By putting the might of an industry giant behind mRNA, Pfizer is making the technology mainstream.

The lack of a track record has prompted some skepticism about the approach, but Dr. Kathrin Jansen, a senior vice president and the head of vaccine research and development at Pfizer, dismissed the criticism.

“That’s not a scientific mindset — that just because it’s new, it will fail,” she said in an interview.

Jansen said Pfizer had placed its bet on mRNA not just because the technology could produce a vaccine quickly, but also because a review of previous work by BioNTech on experimental cancer vaccines suggested the approach could cause a powerful immune response. Before the coronavirus pandemic, the two companies had been collaborating on flu vaccines.

MAKING VACCINES

Vaccines using mRNA consist of genetic material from part of the virus, encased in tiny particles made of fat that help it get into human cells. The mRNA then prompts the cells to churn out a tiny piece of the virus, causing the immune system to attack the real virus if the person is exposed. In essence, the patient’s cells become factories for a harmless fragment of the virus.

These mRNA vaccines set off several different kinds of immune responses, Jansen said, which is important because scientists do not know yet which type will be most potent against the coronavirus.

Jansen described making an mRNA vaccine as a clean, fast process that required a relatively small footprint to produce many doses.

Several other companies are also making mRNA vaccines, and each has its own formulation of the genetic material and types of fat used to encase it.

The large vaccine studies set to begin this month will each include 30,000 people, with some getting placebo shots. The FDA has said that to be considered effective, a coronavirus vaccine should protect 50% of the people who receive it.

Companies hope to show proof of effectiveness by the fall, but that will depend on enrolling enough volunteers in areas where the infection rate is high enough to see a significant difference between the vaccinated people and the placebo group.

“We think we will see the end points, given that the infection rates are going up, up, up,” Jansen said. “If the stars are aligned, it could be next fall. But everything has to be right.”

The agreement with Pfizer, which the company and the Department of Health and Human Services announced Wednesday morning, is the largest one yet for Operation Warp Speed.

“We’ve been committed to making the impossible possible by working tirelessly to develop and produce in record time a safe and effective vaccine to help bring an end to this global health crisis,” Dr. Albert Bourla, Pfizer’s chairman and chief executive, said in a news release.